In contrast to our results, Javed et al., 2019 performed RCT, comparing hormonal and metabolic effect of empagliflozin versus metformin in PCOS women; where they did not report significant changes in fasting glucose, insulin, or lipids after 3 months of treatment. This evidence concerns the gene INS and polycystic ovary syndrome.